Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2023 | 1 |
2024 | 3 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3-ITD: A multicenter phase 2 study.
J Intern Med. 2024 Feb;295(2):216-228. doi: 10.1111/joim.13738. Epub 2023 Oct 29.
J Intern Med. 2024.
PMID: 37899297
Clinical Trial.
Mutations of epigenetic modifier genes predict poor outcome in adult acute lymphoblastic leukemia.
Ou J, Deng S, Ding C, Cai Z, Chen J, Huang Z, Xu X, Li J, Wu Z, Tang B, Zhang T, Wang Z, Zhou Y, Xuan L, Liu Q, Zhou H.
Ou J, et al.
Ann Hematol. 2024 Mar 7. doi: 10.1007/s00277-024-05681-4. Online ahead of print.
Ann Hematol. 2024.
PMID: 38451293
Item in Clipboard
STAT5 phosphorylation plus minimal residual disease defines a novel risk classification in adult B-cell acute lymphoblastic leukaemia.
Xu X, Huang Z, Ding C, Deng S, Ou J, Cai Z, Zhou Y, Liang H, Chen J, Wang Z, Liu X, Xuan L, Liu Q, Zheng Z, Li Z, Zhou H.
Xu X, et al.
Br J Haematol. 2024 Apr 19. doi: 10.1111/bjh.19467. Online ahead of print.
Br J Haematol. 2024.
PMID: 38639167
Item in Clipboard
Cite
Cite